Treatment of obese insulin-resistant mice with an allosteric MAPKAPK2/3 inhibitor lowers blood glucose and improves insulin sensitivity

Diabetes

Volumn 64, Issue 10, 2015, Pages 3396-3405

  Ozcan, Lale ^a   Xu, Xiaoming ^a   Deng, Shi Xian ^a   Ghorpade, Devram S ^a   Thomas, Tiffany ^a,b   Cremers, Serge ^a,b   Hubbard, Brian ^c   Serrano Wu, Michael H ^c   Gaestel, Matthias ^d   Landry, Donald W ^a   Tabas, Ira ^a,b  

^a Columbia University ^*  (United States)

^b Department of Medicine   (United States)

^c Tabomedex Biosciences   (United States)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FORSKOLIN; GLUCOSE; INSULIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; ENZYME INHIBITOR; GLUCOSE BLOOD LEVEL; MAP-KINASE-ACTIVATED KINASE 2; MAP-KINASE-ACTIVATED KINASE 3; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; KNOCKOUT MOUSE; MOUSE MUTANT;

ANIMALS; BLOOD GLUCOSE; ENZYME INHIBITORS; INSULIN RESISTANCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, KNOCKOUT; MICE, OBESE; PROTEIN-SERINE-THREONINE KINASES;

EID: 84982190197     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1945     Document Type: Article

References (42)

1. Kuritzky L, Samraj GP. Enhanced glycemic control with combination therapy for type 2 diabetes in primary care. Diabetes Ther 2011;2:162-177
2. Lin HV, Accili D. Hormonal regulation of hepatic glucose production in health and disease. Cell Metab 2011;14:9-19
3. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 2012;122:4-12
4. D'Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab 2011;13(Suppl. 1):126-132
5. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306:457-461
6. Gregor MF, Yang L, Fabbrini E, et al. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes 2009;58:693-700
7. Fu S, Yang L, Li P, et al. Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature 2011;473:528-531
8. Park SW, Zhou Y, Lee J, Lee J, Ozcan U. Sarco (endo) plasmic reticulum Ca212ATPase 2b is a major regulator of endoplasmic reticulum stress and glucose homeostasis in obesity. Proc Natl Acad Sci U S A 2010;107:19320-19325
9. Mu J, Qureshi SA, Brady EJ, et al. Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist. PLoS ONE 2012;7:e49572
10. Sloop KW, Cao JX, Siesky AM, et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 2004;113:1571-1581
11. Han S, Akiyama TE, Previs SF, et al. Effects of small interfering RNA-mediated hepatic glucagon receptor inhibition on lipid metabolism in db/db mice. J Lipid Res 2013;54:2615-2622
12. Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006;313:1137-1140
13. Ozcan L, Wong CC, Li G, et al. Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity. Cell Metab 2012;15:739-751
14. Ozcan L, Cristina de Souza J, Harari AA, Backs J, Olson EN, Tabas I. Activation of calcium/calmodulin-dependent protein kinase II in obesity mediates suppression of hepatic insulin signaling. Cell Metab 2013;18:803-815
15. Dulos J, Wijnands FP, van den Hurk-van Alebeek JA, et al. p38 inhibition and not MK2 inhibition enhances the secretion of chemokines from TNF-a activated rheumatoid arthritis fibroblast-like synoviocytes. Clin Exp Rheumatol 2013;31:515-525
16. Ronkina N, Menon MB, Schwermann J, et al. MAPKAP kinases MK2 and MK3 in inflammation: complex regulation of TNF biosynthesis via expression and phosphorylation of tristetraprolin. Biochem Pharmacol 2010;80:1915-1920
17. Heinrichsdorff J, Luedde T, Perdiguero E, Nebreda AR, Pasparakis M. p38 alpha MAPK inhibits JNK activation and collaborates with IkappaB kinase 2 to prevent endotoxin-induced liver failure. EMBO Rep 2008;9:1048-1054
18. Hui L, Bakiri L, Mairhorfer A, et al. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun. pathway. Nat Genet 2007;39:741-749
19. Huang X, Zhu X, Chen X, et al. A three-step protocol for lead optimization: quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors. Bioorg Med Chem Lett 2012;22:65-70
20. Ronkina N, Kotlyarov A, Dittrich-Breiholz O, et al. The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol Cell Biol 2007;27:170-181
21. Boden G, She P, Mozzoli M, et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes 2005;54:3458-3465
22. Achard CS, Laybutt DR. Lipid-induced endoplasmic reticulum stress in liver cells results in two distinct outcomes: adaptation with enhanced insulin signaling or insulin resistance. Endocrinology 2012;153:2164-2177
23. Gaestel M. MAPKAP kinases - MKs - two's company, three's a crowd. Nat Rev Mol Cell Biol 2006;7:120-130
24. Ayala JE, Streeper RS, Desgrosellier JS, et al. Conservation of an insulin response unit between mouse and human glucose-6-phosphatase catalytic subunit gene promoters: transcription factor FKHR binds the insulin response sequence. Diabetes 1999;48:1885-1889
25. von Groote-Bidlingmaier F, Schmoll D, Orth HM, Joost HG, Becker W, Barthel A. DYRK1 is a co-activator of FKHR (FOXO1a)-dependent glucose-6-phosphatase gene expression. Biochem Biophys Res Commun 2003;300:764-769
26. Streicher JM, Ren S, Herschman H, Wang Y. MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. Circ Res 2010;106:1434-1443
27. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000;49:2063-2069
28. What comes after metformin for type 2 diabetes? Med Lett Drugs Ther 2012;54:58-59
29. Cheung PC, Campbell DG, Nebreda AR, Cohen P. Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha. EMBO J 2003;22:5793-5805
30. Adams RH, Porras A, Alonso G, et al. Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol Cell 2000;6:109-116
31. Jagavelu K, Tietge UJ, Gaestel M, Drexler H, Schieffer B, Bavendiek U. Systemic deficiency of the MAP kinase-activated protein kinase 2 reduces atherosclerosis in hypercholesterolemic mice. Circ Res 2007;101:1104-1112
32. Duraisamy S, Bajpai M, Bughani U, Dastidar SG, Ray A, Chopra P. MK2: a novel molecular target for anti-inflammatory therapy. Expert Opin Ther Targets 2008;12:921-936
33. de Boer JF, Dikkers A, Jurdzinski A, et al. Mitogen-activated protein kinaseactivated protein kinase 2 deficiency reduces insulin sensitivity in high-fat dietfed mice. PLoS ONE 2014;9:e106300
34. Lehner MD, Schwoebel F, Kotlyarov A, Leist M, Gaestel M, Hartung T. Mitogen-activated protein kinase-activated protein kinase 2-deficient mice show increased susceptibility to Listeria monocytogenes infection. J Immunol 2002;168:4667-4673
35. Fredman G, Ozcan L, Spolitu S, et al. Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calciumactivated kinase pathway. Proc Natl Acad Sci U S A 2014;111:14530-14535
36. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature 2014;510:92-101
37. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 2013;339:166-172
38. DeMong D, Dai X, Hwa J, et al. The discovery of N-((2H-tetrazol-5-yl) methyl) - 4-((R)-1-((5r, 8R)-8-(tert-butyl)-3-(3, 5-dichlorophenyl)-2-oxo-1, 4-diazaspiro[4.5]dec-3-en-1-yl)-4, 4-dimethylpentyl) benzamide (SCH 900822): a potent and selective glucagon receptor antagonist. J Med Chem 2014;57:2601-2610
39. Xiong Y, Guo J, Candelore MR, et al. Discovery of a novel glucagon receptor antagonist N-[(4-(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl) - 1H-pyrazol-1-yl]ethylphenyl) carbonyl]-b-alanine (MK-0893) for the treatment of type II diabetes. J Med Chem 2012;55:6137-6148
40. Qureshi SA, Rios Candelore M, Xie D, et al. A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 2004;53:3267-3273
41. Gelling RW, Du XQ, Dichmann DS, et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 2003;100:1438-1443
42. Longuet C, Sinclair EM, Maida A, et al. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab 2008;8:359-371